158 related articles for article (PubMed ID: 37051534)
1. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset.
Prabhash K; Tan DSW; Soo RA; Sitthideatphaiboon P; Chen YM; Voon PJ; Syahruddin E; Chu S; Huggenberger R; Cho BC
Front Oncol; 2023; 13():1117348. PubMed ID: 37051534
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort.
Aboelhassan R; Sobeih ME; El-Din MA; Ghali RR; El-Din IS; Khorshid O; Mokhtar M; Rabea AM; Belal A; Azim HA; Abdullah M; Elnahas T; Tawfik H; Abdelwahab S; Elsaid AA; Hashem T; Mancy M; Farag H
Ther Adv Med Oncol; 2023; 15():17588359231212182. PubMed ID: 38028146
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study.
Jazieh AR; Onal HC; Tan DSW; Soo RA; Prabhash K; Kumar A; Huggenberger R; Robb S; Cho BC
J Thorac Oncol; 2021 Oct; 16(10):1733-1744. PubMed ID: 34051381
[TBL] [Abstract][Full Text] [Related]
4. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.
Jazieh AR; Onal HC; Tan DS; Soo RA; Prabhash K; Kumar A; Huggenberger R; Cho BC
Ther Adv Med Oncol; 2022; 14():17588359221122720. PubMed ID: 36119641
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort.
Van Dao T; Diep TB; Le Phuong T; Huggenberger R; Kumar A
Front Oncol; 2022; 12():842296. PubMed ID: 35677172
[TBL] [Abstract][Full Text] [Related]
6. Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
Jazieh AR; Sağlam EK; Önal HC; Abdelkader Y; Gaafar R; Dawoud E; Nassar M; Alshorbagy D; El Ashry H; Elsayed M
Clin Lung Cancer; 2022 Jun; 23(4):364-373. PubMed ID: 35277345
[TBL] [Abstract][Full Text] [Related]
7. Real-world KINDLE-Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non-small-cell lung cancer.
Martin CM; Puello-Guerrero A; Mas-Lopez LA; Campos-Gómez S; Orlando-Orlandi FJ; Tejado Gallegos LF; Huggenberger R
Cancer Med; 2023 Jan; 12(2):1247-1259. PubMed ID: 35789068
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
[TBL] [Abstract][Full Text] [Related]
9. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study.
Su PL; Chang GC; Hsiao SH; Hsia TC; Lin MC; Lin MH; Shih JY; Yang CT; Yang SH; Chen YM
JTO Clin Res Rep; 2022 Mar; 3(3):100292. PubMed ID: 35252898
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.
Provencio M; Carcereny E; López Castro R; Calvo V; Rodríguez Abreu D; Cobo M; Ortega AL; Bernabé R; Guirado M; Massutí B; Del Barco-Morillo E; Bosch-Barrera J; Camps C; Carroll R; Rault C; Chaib C; Penrod J; Vo L; Ralphs E; Daumont MJ
Transl Lung Cancer Res; 2023 Oct; 12(10):2113-2128. PubMed ID: 38025806
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Cronin-Fenton D; Dalvi T; Movva N; Pedersen L; Hansen H; Fryzek J; Hedgeman E; Mellemgaard A; Rasmussen TR; Shire N; Hamilton-Dutoit S; Nørgaard M
Sci Rep; 2021 Aug; 11(1):16892. PubMed ID: 34413420
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
14. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
15. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
17. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
19. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
20. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
